Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.61 |
| ▸ | PDE4A | P27815 | 12/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | TNF | P01375 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4855594 | 0.91 | PDE4A (0.64) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL536975 | 0.91 | PDE4B (0.68) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3131798 | 0.90 | PDE4A (0.66) | PDE4BPDE4CPDE4APDE4DTNF | |
| SCHEMBL23392615 | 0.89 | PDE4A (0.77) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3127985 | 0.89 | PDE4A (0.75) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL4919811 | 0.89 | PDE4A (0.63) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL4851023 | 0.88 | PDE4A (0.64) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3124805 | 0.87 | PDE4A (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL8267926 | 0.87 | PDE4B (0.64) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537443 | 0.86 | PDE4B (0.61) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1510518-B1 | Substituted 1,3,4-oxadiazoles for use in the treatement or prophylaxis of diseases | CELGENE CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-1462449-B9 | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels | CELGENE CORP (US) | 2010-03-10 | — | — | EP | disclosed |
| EP-1462449-B1 | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels | CELGENE CORP (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1510518-A2 | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels | CELGENE CORPORATION (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1242413-B1 | SUBSTITUTED 1,3,4-OXADIAZOLES AND A METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-1462449-A1 | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels | CELGENE CORPORATION (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6326388-B1 | ANTIINFLAMMATORY AGENTS | CELGENE CORPORATION | 2001-12-04 | — | — | US | disclosed |